Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

QUICK LINKS
Get Product Support Find Technical Documents Find Certificates of Compliance Get Training Start a Career With Us

LATEST NEWS

A Look Inside Terumo BCT's Impact on Convalescent Plasma for COVID-19

First COVID-19 Patient Receives Therapy Targeting Cytokine Storm Under FDA EUA

Terumo BCT’s Mirasol reduces the virus causing COVID-19 below the limit of detection in plasma and platelets

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide

Terumo BCT’s Mirasol Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets

Terumo BCT and Marker Therapeutics received the first device FDA Emergency Use Authorization (EUA) to treat acute respiratory failure in COVID-19 patients

Terumo BCT Message: COVID-19

Terumo BCT’s Mirasol® Pathogen Reduction Technology (PRT) System Demonstrates Reduced Risk of Transfusion Transmission of MERS-CoV, a strain of Coronavirus
UNLOCKING THE POTENTIAL OF BLOOD


{{'MP_FOOTER_MARKET_DISCLAIMER' | translate}}

{{l.name}}
{{'MP_FOOTER_TBCT_COPYRIGHT' | translate}}
{{'SEARCH_MODAL_TITLE' | translate }}
{{s.Query|stripSpecialChars}}
{{'SEARCH_MODAL_OR' | translate }}
{{'SEARCH_MODAL_BROWSE' | translate }}
{{productCode.RefinementName}}
{{categoryCode.RefinementName}}
{{segmentCode.RefinementName}}
{{'SEARCH_MODAL_SHOW_BROWSE_RESULTS' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}